Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Marcella, Fassò"'
Autor:
Luciana Molinero, Yijin Li, Ching-Wei Chang, Sophia Maund, Maureen Berg, Jeanne Harrison, Marcella Fassò, Carol O’Hear, Priti Hegde, Leisha A. Emens
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Abstract Background Metastatic TNBC (mTNBC) has a poor prognosis and few treatment options. The anti-PD-L1 antibody atezolizumab demonstrated clinical activity in mTNBC patients with PD-L1-positive tumor-infiltrating immune cells. The current study d
Externí odkaz:
https://doaj.org/article/dd95d67f18f340099d4709fdb5d1dae3
Autor:
Thomas Powles, Susheela Carroll, Marcella Fassò, Sujata Narayanan, Carol O'Hear, Sanjeev Mariathasan, Edward E. Kadel, Kobe Yuen, Indrani Sarkar, Joseph W. Kim, Michael Gordon, Jean-Pierre Delord, Paul Conkling, Lauren C. Harshman, John Powderly, Fadi Braiteh, David R. Shaffer, Yohann Loriot, Daniel P. Petrylak
Supplement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21f20f4e26dac7ce017a501823fa9fa0
https://doi.org/10.1158/1078-0432.22480052.v1
https://doi.org/10.1158/1078-0432.22480052.v1
Autor:
F. Stephen Hodi, Priti S. Hegde, Daniel S. Chen, Carol O'Hear, Marcella Fassò, Marcus Ballinger, Indrani Sarkar, John D. Powderly, David F. McDermott, Harriet M. Kluger, Eva Muñoz-Couselo, Jeffrey A. Sosman, Christopher R. Bolen, Luciana Molinero, Omid Hamid
Purpose:Atezolizumab [anti–programmed death-ligand 1 (PD-L1)] selectively targets PD-L1 to block its interaction with receptors programmed death 1 and B7.1, thereby reinvigorating antitumor T-cell activity. We evaluated the long-term safety and act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10746515c079c17f9a6ccbb5603f4804
https://doi.org/10.1158/1078-0432.c.6527925.v1
https://doi.org/10.1158/1078-0432.c.6527925.v1
Autor:
F. Stephen Hodi, Priti S. Hegde, Daniel S. Chen, Carol O'Hear, Marcella Fassò, Marcus Ballinger, Indrani Sarkar, John D. Powderly, David F. McDermott, Harriet M. Kluger, Eva Muñoz-Couselo, Jeffrey A. Sosman, Christopher R. Bolen, Luciana Molinero, Omid Hamid
Figures S1-S4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01ed4fcdf75666e00700454e15846c60
https://doi.org/10.1158/1078-0432.22471542
https://doi.org/10.1158/1078-0432.22471542
Autor:
F. Stephen Hodi, Priti S. Hegde, Daniel S. Chen, Carol O'Hear, Marcella Fassò, Marcus Ballinger, Indrani Sarkar, John D. Powderly, David F. McDermott, Harriet M. Kluger, Eva Muñoz-Couselo, Jeffrey A. Sosman, Christopher R. Bolen, Luciana Molinero, Omid Hamid
Tables S1-S4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d649a52c6adc2a7c3b695bdfbc42a0d4
https://doi.org/10.1158/1078-0432.22471545
https://doi.org/10.1158/1078-0432.22471545
Autor:
Thomas Powles, Susheela Carroll, Marcella Fassò, Sujata Narayanan, Carol O'Hear, Sanjeev Mariathasan, Edward E. Kadel, Kobe Yuen, Indrani Sarkar, Joseph W. Kim, Michael Gordon, Jean-Pierre Delord, Paul Conkling, Lauren C. Harshman, John Powderly, Fadi Braiteh, David R. Shaffer, Yohann Loriot, Daniel P. Petrylak
Purpose:Atezolizumab [anti–programmed death-ligand 1 (anti-PD-L1)] is well tolerated and efficacious in multiple cancers, but has not been previously evaluated in metastatic castration-resistant prostate cancer (mCRPC). This study examined the safe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13798053ba75b9ddf6160ccc2387be26
https://doi.org/10.1158/1078-0432.c.6530360.v1
https://doi.org/10.1158/1078-0432.c.6530360.v1
Autor:
James P. Allison, Larry Norton, Marcella Fassò, Anne E. Trumble, Elena N. Petre, Stephen B. Solomon, Rebecca Waitz
PDf file - 198K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::392d24cbfb19b12db3cf28f4daf8a17e
https://doi.org/10.1158/0008-5472.22393521.v1
https://doi.org/10.1158/0008-5472.22393521.v1
Autor:
Edward Cha, Su Pin Choo, Sun Young Rha, Kei Muro, Anand D. Jeyasekharan, Arne Fabritius, Joe Yeong, Manjie Xing, Filippo Pietrantonio, Angie Lay-Keng Tan, Aditi Qamra, Zul Fazreen Adam Isa, Kalpana Ramnarayanan, Jimmy Bok Yan So, Mark De Simone, Yukiya Narita, Radhika Patnala, Monica Niger, David Tai, Jonathan Göke, Luciana Molinero, Jeeyun Lee, Kie-Kyon Huang, Deniz Demircioğlu, Yu Amanda Guo, Meghna Das Thakur, Wei Peng Yong, Qingfeng Chen, Patrick Tan, Marcella Fassò, Zhisheng Her, Vikrant Kumar, Xuewen Ong, Weiwei Zhai, Cedric Chuan Young Ng, Jia Qi Lim, Anders Jacobsen Skanderup, Raghav Sundar
Publikováno v:
Gut. 71:1277-1288
ObjectivesEpigenomic alterations in cancer interact with the immune microenvironment to dictate tumour evolution and therapeutic response. We aimed to study the regulation of the tumour immune microenvironment through epigenetic alternate promoter us
Autor:
Mahrukh A, Huseni, Lifen, Wang, Joanna E, Klementowicz, Kobe, Yuen, Beatrice, Breart, Christine, Orr, Li-Fen, Liu, Yijin, Li, Vinita, Gupta, Congfen, Li, Deepali, Rishipathak, Jing, Peng, Yasin, Şenbabaoǧlu, Zora, Modrusan, Shilpa, Keerthivasan, Shravan, Madireddi, Ying-Jiun, Chen, Eleanor J, Fraser, Ning, Leng, Habib, Hamidi, Hartmut, Koeppen, James, Ziai, Kenji, Hashimoto, Marcella, Fassò, Patrick, Williams, David F, McDermott, Jonathan E, Rosenberg, Thomas, Powles, Leisha A, Emens, Priti S, Hegde, Ira, Mellman, Shannon J, Turley, Mark S, Wilson, Sanjeev, Mariathasan, Luciana, Molinero, Mark, Merchant, Nathaniel R, West
Publikováno v:
Cell reports. Medicine.
Although immune checkpoint inhibitors (ICIs) are established as effective cancer therapies, overcoming therapeutic resistance remains a critical challenge. Here we identify interleukin 6 (IL-6) as a correlate of poor response to atezolizumab (anti-PD
Autor:
Yohann Loriot, Indrani Sarkar, Daniel P. Petrylak, Joseph Kim, Paul Conkling, Thomas Powles, Susheela Carroll, Lauren C. Harshman, Jean-Pierre Delord, Edward E. Kadel, Sujata Narayanan, Marcella Fassò, David R. Shaffer, Michael S. Gordon, Sanjeev Mariathasan, Kobe C. Yuen, John D. Powderly, Fadi Braiteh, Carol O'Hear
Publikováno v:
Clinical Cancer Research. 27:3360-3369
Purpose: Atezolizumab [anti–programmed death-ligand 1 (anti-PD-L1)] is well tolerated and efficacious in multiple cancers, but has not been previously evaluated in metastatic castration-resistant prostate cancer (mCRPC). This study examined the saf